ICARE Social Media Post February 2020

Updated Pancreatic Cancer Screening Guidelines through the International Cancer of the Pancreas Screening (CAPS) Consortium

The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated pancreatic cancer screening recommendations. The recommendations include:

  • Screening with MRI/magnetic retrograde cholangiopancreaography (MRCP) and/or endoscopic ultrasound (EUS)

The screening was recommended for the following individuals:

  • CDKN2A and STK11 mutation carriers starting at age 40
  • BRCA1/2, ATM, PALB2, MLH1, and MSH2 mutation carriers (if they have at least one first-degree relative with pancreatic cancer) starting at age 45-50 or 10 years younger than the youngest affected relative

Check out the full article at https://www.ncbi.nlm.nih.gov/pubmed/31672839

 

These guidelines differ from current NCCN Pancreatic Cancer Screening Guidelines as follows:

STK11:

  • CAPS: Consider screening beginning at age 40
  • NCCN: Consider screening beginning at age 30-35

MSH6, EPCAM, TP53:

  • CAPS: Not included
  • NCCN: Consider screening beginning at age 50

CDKN2A, BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6:

  • Screening recommendations remain the same as CAPS

Check out NCCN guidelines by creating a FREE account at https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.

Permanent link to this article: https://inheritedcancer.net/post2420/